EFCCA is involved in an exciting EU Research Project under the Innovative Medicines Initiative (IMI 2) (Horizon 2020).
The ImmUniverse project main goal is the improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis. New insights into disease severity and progression will enable personalised therapy for each individual patient.
Through molecular profiling techniques, the project will identify signatures of biomarkers and mechanistic principles which reveal information on disease severity and progression enabling personalised therapy decisions for each patient at the right time.
Immune-mediated inflammatory diseases (IMIDs) are an increasing medical burden in industrialised countries worldwide. They are characterised by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which often cannot be adequately tailored to individual patients.Hence, an in-depth understanding of this heterogeneity and the biomarkers which predict disease control and therapy response over time are important prerequisites for future precision medicine strategies in IMIDs. The pathogenic components (“omics”) responsible for the disease outcome in each individual patient, i.e. environment, genes, gut microbiota or the immune system, are remarkably multifactorial, with thousands of constituents all interacting with and impacting on each other.
The project team comprises 16 academic partners, led by Humanitas University, five industrial project partners, two small and medium-sized enterprises as well three European patient organisations to ensure efficient dialogue and a continuous focus on the actual needs of patients living with Ulcerative Colitis and Atopic Dermatitis. The project will run for a period of five years.
Patients will be represented by EFCCA, EFA (European Federation of Allergy and Airways Diseases while EPF (European Patient Forum) will support in the dissemination of the project results.
EFCCA and EFA will be involved in the Work Package 1 (WP1) and will join efforts to assure that all the material addressed to patients is translated into a lay language and that publications and outcomes are made easily available for the patient community.
Publication of the ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases (This has been published on the Open Science Platform, Frontiers)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853995. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.